key: cord-0334570-1nzqee4x authors: Kvaerner, A. S.; Birkeland, E.; Bucher-Johannessen, C.; Vinberg, E.; Nordby, J. I.; Kangas, H.; Bemanian, V.; Ellonen, P.; Botteri, E.; Natvig, E.; Rognes, T.; Hovig, E.; Lyle, R.; Ambur, O. H.; de Vos, W. M.; Bultmann, S.; Hjartaaker, A.; Landberg, R.; Song, M.; Ursin, G.; Ranheim Randel, K.; de Lange, T.; Hoff, G.; Holme, O.; Berstad, P.; Rounge, T. B. title: The CRCbiome study: a large prospective cohort study examining the role of lifestyle and the gut microbiome in colorectal cancer screening participants date: 2020-12-24 journal: nan DOI: 10.1101/2020.12.22.20248658 sha: 0aa2c1104ba006fc7408bfdbc971a77b8ff75c1f doc_id: 334570 cord_uid: 1nzqee4x Background: Colorectal cancer (CRC) screening reduces CRC incidence and mortality. However, current screening methods are either hampered by invasiveness or suboptimal performance, limiting their effectiveness as primary screening methods. To aid in the development of a non-invasive screening test with improved sensitivity and specificity, we have initiated a prospective biomarker study (CRCbiome), nested within a large randomized CRC screening trial in Norway. We aim to develop a microbiome-based classification algorithm to identify advanced colorectal lesions in screening participants testing positive for an immunochemical fecal occult blood test (FIT). We will also examine interactions with host factors, diet, lifestyle and prescription drugs. The prospective nature of the study also enables the analysis of changes in the gut microbiome following the removal of precancerous lesions. Methods: The CRCbiome study recruits participants enrolled in the Bowel Cancer Screening in Norway (BCSN) study, a randomized trial initiated in 2012 comparing once-only sigmoidoscopy to repeated biennial FIT, where women and men aged 50-74 years at study entry are invited to participate. Since 2017, participants randomized to FIT screening with a positive test result have been invited to join the CRCbiome study. Self-reported diet, lifestyle and demographic data are collected prior to colonoscopy after the positive FIT-test (baseline). Screening data, including colonoscopy findings are obtained from the BCSN database. Fecal samples for gut microbiome analyses are collected both before and 2 and 12 months after colonoscopy. Samples are analyzed using metagenome sequencing, with taxonomy profiles, and gene and pathway content as primary measures. CRCbiome data will also be linked to national registries to obtain information on prescription histories and cancer relevant outcomes occurring during the 10 year follow-up period. Discussion: The CRCbiome study will increase our understanding of how the gut microbiome, in combination with lifestyle and environmental factors, influences the early stages of colorectal carcinogenesis. This knowledge will be crucial to develop microbiome-based screening tools for CRC. By evaluating biomarker performance in a screening setting, using samples from the target population, the generalizability of the findings to future screening cohorts is likely to be high. Keywords: Diet, lifestyle, prescription drugs, gut microbiome, metagenomics sequencing, 91 biomarkers, screening, FIT, iFOBT, colonoscopy, adenoma, colorectal cancer, advanced 92 neoplasia 93 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.22.20248658 doi: medRxiv preprint 5 Background 94 Colorectal cancer (CRC) is a major global health burden, accounting for nearly 10% of all 95 cancers diagnosed and cancer-related deaths each year (1). Although a decline in the age-96 standardized mortality rate has been observed over the past two to three decades in many 97 countries (2-4), death rates remain high, particularly when diagnosed at later stages (5-year 98 survival rate of 13% for metastatic disease compared to 90% when diagnosed at a localized 99 stage) (1,5). The significant contribution to global cancer deaths, together with the worrying 100 rise in incidence rates seen globally (3), especially the recent increase among younger age 101 groups (6,7), highlights the need for widespread prevention strategies that are both effective 102 and feasible on a large-scale basis. 103 There are two major precursor lesions of CRC: adenomatous polyps, accounting for the 104 majority of cases, and serrated lesions, estimated to underlie up to 30% of CRC (8). The 105 progression of precursor lesions to CRC is a long-term process, spanning a period of 10-15 106 years for most lesions (9). During this long latency period, most cancers develop 107 asymptomatically, making them difficult to detect at a preclinical stage. Therefore, 108 international guidelines recommend screening, with the aim of detection and removal of 109 precancerous lesions to prevent cancer from occurring, or to detect cancer at the earliest stage 110 possible (10-13). 111 Screening has been shown to reduce both CRC incidence (14-17) and mortality (14-21) in 112 randomized controlled trials, even though current screening methods have known limitations 113 (22) . At present, the most commonly used screening method is the fecal immunochemical test 114 (FIT) for occult blood, having mostly replaced the less sensitive guaiac-based fecal occult 115 blood test (gFOBT) (23). Despite being more sensitive, performance characteristics are still 116 suboptimal with regards to sensitivity and specificity, resulting in both missed neoplasms and 117 unnecessary colonoscopy referrals (22). Of particular concern has been the limited 118 performance in detecting precancerous lesions, representing a missed opportunity given the 119 great potential for cancer prevention following removal of these lesions. There is also 120 evidence that current screening methods perform worse for right-sided tumors, compared to 121 left-sided ones (24), as well as in women compared to men (25,26). Thus, there is a 122 requirement for screening methods and tools with improved performance for the entire 123 screening population. The connection between a potentially pathogenic gut microbiome and CRC has resulted in a 143 growing interest in the use of gut microbial biomarkers as screening tests for early detection 144 Long-term outcomes (i.e. incidence and mortality of advanced colorectal lesions) will be 167 examined by means of passive follow-up using data from the national registries. The outcome 168 assessment will be aligned with the 10 year follow-up of the Bowel Cancer Screening in 169 Norway (BCSN) trial (46), from which the CRCbiome study recruits participants. 170 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint 191 Participants are invited to the CRCbiome study prior to their colonoscopy examination. The 192 invitation includes an information letter and two questionnaires (further details given below). . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2020. The main inclusion and exclusion criteria for the BCSN trial and the CRCbiome study are 217 listed in Table 1 . 218 Eligible subjects are invited after being informed about their positive FIT test and a 220 colonoscopy appointment has been scheduled. Invitations to the CRCbiome study, including 221 the two questionnaires, are sent out by mail a minimum of four days prior to the colonoscopy. 222 Returning at least one of the two questionnaires is regarded as a consent to the study, and 223 includes permission to collect, analyze and store fecal samples, and to retrieve information 224 from questionnaires and health registries. 225 Both the BCSN trial and the CRCbiome study have been approved by the Regional 226 For the first two aims, the outcome variable will be defined based on the colonoscopy result. 231 Participants will be grouped into four main categories: no confirmed neoplastic findings 232 (Group 1); non-advanced lesions (Group 2); advanced lesions (Group 3); and CRC (Group 4) 233 (Table 2) . We may further subdivide lesions by clinicopathological features, including 234 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.22.20248658 doi: medRxiv preprint histopathological subtype (e.g. adenomas versus serrated lesions) and site of occurrence 235 (proximal versus distal colon). Also of interest is the potential for distinct roles of 236 environmental factors and the gut microbiome in the two main pathways of colorectal 237 carcinogenesis: the adenoma-carcinoma pathway, and the serrated carcinoma pathway. 238 For the third aim, the outcome variable will be defined based on the metagenome data. We 239 will monitor several aspects of the gut microbiome, leveraging information derived from 240 metagenomic sequencing to describe the presence of bacterial strains and the functional 241 potential in paired samples during re-establishment of the gut microbiome following bowel 242 cleansing and colonoscopy. 243 Long-term effects in the study will be assessed 10 years after recruitment is completed. This 244 will include an investigation of incidence and mortality of advanced colorectal lesions. 245 Assessment of clinical data 247 As part of the BCSN (46), participants are contacted by a study nurse prior to follow-up 248 colonoscopy, to obtain information on medical history. This includes prior colonoscopies and 249 CT colonographies, comorbidities, drug use, gastrointestinal symptoms, smoking habits, and 250 body weight and height (Table 3) . A variety of data are collected in relation to the follow-up 251 colonoscopy, including screening outcomes (i.e. presence and clinicopathological 252 characterization of detected lesions) and cgaracteristics relevant to the endoscopic procedure 253 (Table 3) . For all lesions detected, size, location, appearance, technique used for removal and 254 tissue sampling, and completeness of removal are recorded. Both the medical history data and 255 data collected as part of the follow-up colonoscopy are entered into a dedicated database by 256 the responsible health care provider. A complete overview of the data collected in the BCSN 257 trial can be found elsewhere (46). 258 Biological sampling and gut microbiome analysis 259 Sampling kits for stool sample collection are mailed to the participants three times during the 261 study period. No restrictions on diet or medication use are required prior to sampling. Stool is 262 collected using plastic sticks, which collect about 10 mg stool. The stool is then stored in 2 ml 263 of buffer containing HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), BSA 264 (Bovine serum albumin) and sodium azide. Samples are then packed in padded envelopes and 265 returned by mail to a laboratory at Oslo University Hospital for analysis and further storage at 266 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2020. -80 °C. Shipping time is estimated to 3-10 days. Immunochemical testing for blood in feces is 267 performed continuously using the OC-Sensor Diana (Eiken Chemical, Tokyo, Japan) as 268 samples are received at the laboratory. 269 Thawed samples are transferred to three 500 ml aliquots from the sampling bottle using a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2020. Processing and analysis of sequencing data 313 Sequencing data are transferred to a platform for secure storage and analysis of sensitive 314 research-related data at the University of Oslo (52). The analysis of metagenomic sequencing 315 data is handled in a uniform manner using a customizable workflow manager (53) . To 316 establish a quality-filtered dataset, standard filters are applied: sequences corresponding to 317 adapters used in library preparation, being of low quality (54) and those mapping to the 318 human genome (55), with subsequent quality control of filtered sequencing reads (56). 319 Taxonomic classification and determination of microbial gene content, including functional 320 annotation (e.g. using gene ontology and KEGG databases) will be performed using publicly 321 available tools. Abundance measures will be used to calculate taxonomic and functional alpha 322 and beta diversity, as well as serving as input for machine learning approaches aimed at 323 producing classifiers for high-risk individuals in a data-driven manner. Further metagenome-324 derived measures may include identification of metagenome-assembled genomes, strain-level 325 analysis and description of the gut virome. 326 Questionnaires 327 Two questionnaires are used to collect data on diet, lifestyle and demographic data: a food 328 frequency questionnaire (FFQ) and a general lifestyle and demographics questionnaire 329 (LDQ). Self-reported dates of questionnaire completion are registered in the project database. 330 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.22.20248658 doi: medRxiv preprint Returned questionnaires are reviewed manually before scanning and further processing. In 331 cases of low-quality data, participants are contacted for clarification. 332 Dietary intake is assessed using a semiquantitative, 14-page FFQ, designed to assess the 334 habitual diet during the preceding year. The questionnaire is a modified version of an FFQ 335 developed and validated by the Department of Nutrition, University of Oslo (57-62). The 336 questionnaire has been validated for both energy intake (57-59), intake of macro and 337 micronutrients (57,59,62), as well as selected food items and groups (59-62). The 338 questionnaire includes 23 main questions, covering a total of 256 food items, as well as a free-339 text field for entries of food items not covered by the questionnaire. For each food item 340 (except one on preferred types of fat for cooking), participants are asked to record frequency 341 of consumption, ranging from never/seldom to several times a day, and/or amount, typically 342 as portion size given in various household units (e.g. deciliters, glasses, cups, spoons). In 343 total, there are 249 questions on frequency, 204 on portion size, one on preferences and nine 344 other, mostly related to meal patterns (Additional file 1, supplementary Table 1) . 345 As with any dietary assessment method, the FFQ is prone to errors due to inaccurate reporting 346 and missing answers. Therefore, to mitigate such errors, a standardized framework for how to 347 review and evaluate FFQ quality has been developed. the past years' physical activity level and lastly use of regular and cultured milk, which is not 372 completely covered in the FFQ (see Table 3 for a detailed overview). In the questions 373 concerning smoking and snus habits, participants are asked to recall their current habits, 374 including the daily number of cigarettes/snus portions, as well as years since possible 375 cessation and total years of use. Questionnaires are scanned and processed using the Cardiff 376 TeleForm program (InfoShare, Oslo, Norway). 377 Data collected in the CRCbiome study will be linked to national registries, including the is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.22.20248658 doi: medRxiv preprint between drug use, the gut microbiome and advanced colorectal lesions. Initially, we will 395 perform drug-wide association analyses to screen for potential associations, adjusting for key 396 covariates. Detected associations will then be examined in detail, including a more refined 397 categorization of drug variables, robust covariate adjustments as well as the analysis of timing 398 and dose-response relations. Prescription histories will also be used as a proxy for life-long 399 burden of chronic diseases. Death Registry and coded using the same ICD-10 categories as for the incidence data. 410 To facilitate project administration, including recruitment and follow-up of participants, 412 custom software has been developed. This application communicates with two project 413 specific databases (i.e. the BCSN and CRCbiome databases). Only authorized data manager 414 personnel have complete access to the datasets. A simplified version of the data generation 415 process is depicted in Figure 2 . 416 In line with common practice for linkage with national registries (76), linked data will receive 417 unique ID numbers specific to the particular project. Linkage of research data will be 418 performed by the data controller. For the metagenome data, which due to its size cannot be 419 transferred using ordinary methods, linkage will be performed in-house by an independent 420 data manager without access to other parts of the data than those strictly necessary for 421 linkage. 422 All data collected in the CRCbiome study will be stored and analyzed at a platform for secure 423 handling of sensitive research-related data, operated by the University of Oslo (52). Access to 424 research data for external investigators, or use outside of the current protocol, will require 425 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.22.20248658 doi: medRxiv preprint approval from the Norwegian Regional Committee for Medical and Health Research Ethics 426 and a data access committee (information available on the project web site (77)). Research 427 data are not openly available because of the principles and conditions set out in articles 6 (1) 428 (e) and 9 (2) (j) of the General Data Protection Regulation (GDPR). 429 The number of participants to include was chosen with the aim of providing adequate power 431 for the development of a highly sensitive classification algorithm via data-driven analyses of 432 gut metagenomes that will accurately identify FIT-positive individuals in need of clinical 433 intervention. 434 The classifier will be trained using counts of taxonomic units, signature and genes categorized 435 according to gene ontology or pathway membership from metagenomes, FFQ, demographic 436 and lifestyle data as input variables, and advanced colorectal lesions as outcome (i.e. group 437 group 3 and group 4, Table 2 ). The CRC risk classification will be done using machine 438 learning algorithms suited to metagenome data, such as lasso regression (78) have a lower requirement, and we therefore set the expected classifier specificity to 0.75 and a 448 minimally acceptable specificity of 0.6, thus requiring 100 participants with normal findings 449 in the test set. Based on initial recruitment, we expect a participation rate of 58%, with 26% of 450 participants having findings of advanced lesions or CRC ( Table 2) . By inviting 2,700 FIT-451 positive BCSN participants, and splitting the training and test sets 80/20, a projected number 452 of 1,253 and 313 participants will constitute the training and test sets, respectively, which will 453 include adequate numbers of participants with both advanced colorectal lesions and normal 454 findings in the test set. With this sample size, we will also be able to perform stratified 455 analyses. 456 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The study also has some limitations. Exclusive selection of FIT positive participants may 501 limit the generalizability of the findings to those with bleeding neoplastic lesions. 502 Consequently, improvements in diagnostic performance may be limited to specificity, and 503 thus the ability to correctly classify healthy individuals. However, since lesions tend to bleed 504 intermittently (85) and the study aims to identify potential causal pathways, we consider it 505 likely that the identified biomarker also may have improved sensitivity in the screening 506 population as a whole. 507 A further limitation is the lack of information on fecal metrics such as the Bristol stool scale, 508 which has been shown to be an important determinant of microbiota richness and variance 509 (86). However, variation in microbiome profile due to stool consistency could likely be 510 explored by use of gastrointestinal symptoms as a surrogate, data on which is available in the 511 BCSN database. 512 Lastly, lack of follow-up data on diet and lifestyle may complicate the interpretation of 513 microbial changes following colonoscopy. Even though prior studies in comparable study 514 populations show that potential changes in diet and lifestyle following screening are modest 515 (87,88), caution in interpretation of follow-up samples is warranted. 516 The CRCbiome study represents a valuable source of data for further research. An example is 517 access to complete prescription histories from the Norwegian Prescription Database that 518 enables in-depth analyses of associations between a broad range of medications, microbial 519 features and neoplasia risk, both during short and long-term follow-up. The fecal samples 520 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.22.20248658 doi: medRxiv preprint collected are also biobanked and can be used for other purposes beside the study aims of the 521 current protocol. For instance, in addition to metagenome sequencing, the fecal samples can 522 potentially be used for other omics analyses, such as transcriptome and metabolome analysis. 523 All tissue specimens removed during colonoscopy are also available to the project, enabling 524 in-depth molecular profiling. 525 The CRCbiome study investigates the role of the gut microbiome, and its interactions with 527 host factors, diet and lifestyle, in early stage colorectal carcinogenesis. Information obtained 528 from this project will guide the development of a microbial biomarker for accurate detection 529 of advanced colorectal lesions. By performing biomarker discovery within a screening 530 population, the generalizability of the findings to future screening cohorts is likely to be high. 531 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All authors contributed to the study design and protocol. 590 All authors contributed to the writing and approval of the final manuscript 591 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.22.20248658 doi: medRxiv preprint Acknowledgements 592 We would like to aknowledge the devoted secretaries, nurses and doctors at Baerum and Moss 593 hospital, and the biomedical laboratory scientists at Oslo University Hospital for their 594 contributions to this study. We would also like to thank the personnel involved in sequencing 595 all CRCbiome samples at the Sequencing laboratory of Institute for Molecular Medicine 596 Finland FIMM Technology Centre, University of Helsinki. Lastly, we would like to thank 597 each study participoant, as well as all collaborative partners, technicians and students that 598 have, and will, contribute to this study. 599 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.22.20248658 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.22.20248658 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.22.20248658 doi: medRxiv preprint Tables, figure titles and legends . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2020. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.22.20248658 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.22.20248658 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.22.20248658 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.22.20248658 doi: medRxiv preprint Contains the STROBE checklist for observational studies. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.22.20248658 doi: medRxiv preprint Global cancer 601 statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 602 cancers in 185 countries Trends in colorectal cancer mortality in Europe: 605 Retrospective analysis of the WHO mortality database The global, regional, and national burden 608 of colorectal cancer and its attributable risk factors in 195 countries and territories Schmidt 614 LKH VA and SH. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival 615 in the Nordic Countries SEER Cancer Statistics Review Emerging cancer trends among young 622 adults in the USA: analysis of a population-based cancer registry Changes in colorectal cancer incidence in 626 seven high-income countries: a population-based study Role of the Serrated Pathway in Colorectal Cancer 629 Colorectal cancer Screening for colorectal 636 cancer: US preventive services task force recommendation statement Colorectal Cancer Screening and Diagnosis -First Edition. Luxembourg: Office for 640 Official Publications of the European Communities Cancer screening recommendations: An international 642 comparison of high income countries An updated Asia Pacific Consensus Recommendations on 646 colorectal cancer screening Cross 648 AJ. Long term effects of once-only flexible sigmoidoscopy screening after 17 years of 649 follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial Colorectal-Cancer Incidence and Mortality with 653 Screening Flexible Sigmoidoscopy Once-only sigmoidoscopy in colorectal cancer screening: 656 Follow-up findings of the italian randomized controlled trial -SCORE Effect of flexible sigmoidoscopy screening on 660 colorectal cancer incidence and mortality: A randomized clinical trial Reducing 663 mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon 664 Cancer Control Study Randomised study of 666 screening for colorectal cancer with faecal-occult-blood test Survival benefit in a randomized clinical trial of 669 faecal occult blood screening for colorectal cancer Randomised controlled trial of faecal-occult-blood 673 screening for colorectal cancer Strategies for Colorectal Cancer 676 Screening Colorectal cancer screening: A global overview of existing programmes Sensitivity of 682 immunochemical faecal occult blood testing for detecting left-vs right-sided colorectal 683 neoplasia Long-term effectiveness of sigmoidoscopy screening on 687 colorectal cancer incidence and mortality in women and men: A randomized trial Variation of diagnostic performance of fecal 690 immunochemical testing for hemoglobin by sex and age: Results from a large 691 screening cohort The Intestinal Microbiota in Colorectal 693 Cancer Genomic analysis identifies association of 696 Fusobacterium with colorectal carcinoma Fusobacterium nucleatum infection is 699 prevalent in human colorectal carcinoma The human gut microbiome as a 705 screening tool for colorectal cancer A 707 simple and novel fecal biomarker for colorectal cancer: Ratio of Fusobacterium 708 nucleatum to probiotics populations, based on their antagonistic effect Fecal bacteria act as novel biomarkers for noninvasive 712 diagnosis of colorectal cancer Microbiota-based model improves 714 the sensitivity of fecal immunochemical test for detecting colonic lesions Potential of fecal microbiota for early stage detection 718 of colorectal cancer 720 Human gut microbiome and risk for colorectal cancer Colorectal cancer and the human gut microbiome: Reproducibility 724 with whole-genome shotgun sequencing Metagenomic analysis of faecal microbiome as a tool towards targeted non-730 invasive biomarkers for colorectal cancer Shifts in the fecal microbiota associated with 733 adenomatous polyps Environment dominates over host genetics in 736 shaping human gut microbiota Influence of the Gut Microbiome, Diet, and Environment on 738 Risk of Colorectal Cancer Environmental Factors, Gut Microbiota, and Colorectal Cancer 741 Prevention Clinical Gastroenterology and Hepatology. The American 742 Gastroenterological Association International Cancer Microbiome Consortium 746 consensus statement on the role of the human microbiome in carcinogenesis Metagenomic analysis of colorectal cancer datasets 750 identifies cross-cohort microbial diagnostic signatures and a link with choline 751 degradation Meta-analysis of fecal metagenomes reveals global 755 microbial signatures that are specific for colorectal cancer Colorectal cancer screening with repeated fecal 759 immunochemical test versus sigmoidoscopy: baseline results from a randomized trial Norwegian Prescription Database 762 (NorPD) Cancer in Norway 2019 -Cancer incidence, mortality, 764 survival and prevalence in Norway. Oslo Strengthening the Reporting of Observational 767 Studies in Epidemiology (STROBE): Explanation and elaboration Explanation and elaboration STROBE-metagenomics: a STROBE 775 extension statement to guide the reporting of metagenomics studies About TSD Snakemake -A scalable bioinformatics workflow engine Trimmomatic: A flexible trimmer for Illumina 782 sequence data Fast gapped-read alignment with Bowtie 2 Summarize analysis results for 786 multiple tools and samples in a single report Evaluation 788 of a food frequency questionnaire with weighed records, fatty acids, and alpha-789 tocopherol in adipose tissue and serum Validation of energy 791 intake estimated from a food frequency questionnaire: A doubly labelled water study 794 Evaluation of energy and dietary intake estimates from a food frequency questionnaire 795 using independent energy expenditure measurement and weighed food records Evaluation 798 of three dietary assessment methods and serum biomarkers as measures of fruit and 799 vegetable intake, using the method of triads Andersen 801 LF. Relative validity of fruit and vegetable intake estimated from an FFQ, using 802 carotenoid and flavonoid biomarkers and the method of triads Bjerve 805 KS, Hjartåker A. Validation of repeated self-reported n-3 PUFA intake using serum 806 phospholipid fatty acids as a biomarker in breast cancer patients during treatment Norwegian Food Safety Authority. Norwegian Food Composition Database Validation and 811 calibration of food-frequency questionnaire measurements in the Northern Sweden 812 Health and Disease cohort A Search for Recall Bias in a Case-Control Study of Diet and 815 Breast Cancer Nutritional epidemiology Kahle 823 LL, Reedy J. Operationalizing the 2018 World Cancer Research Fund/American 824 Institute for Cancer Research (WCRF/AICR) Cancer Prevention Recommendations: A 825 Standardized Scoring System Dietary patterns 827 of women aged 50-69 years and associations with nutrient intake, sociodemographic 828 factors and key risk factors for non-communicable diseases Lifestyle predictors for non-participation and outcome in the second round of 832 faecal immunochemical test in colorectal cancer screening Collaborating Centre for Drug Statistics Methodology. Structure and principles 836 Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2020 838 Cancer in Norway 2018 -Cancer incidence, mortality, 840 survival and prevalence in Norway. Oslo 842 Data quality at the Cancer Registry of Norway: an overview of comparability, 843 completeness, validity and timeliness Access to data from the Norwegian 845 Prescription Database Cancer Registry of Norway. The microbiome as a colorectal cancer screening 849 biomarker Regression Shrinkage and Selection Via the Lasso Support-vector networks Random forests Neural Networks and Learning Machines. Third Edit. Pearson Prentice Hall XGBoost: A Scalable Tree Boosting System Sample size calculation and re-estimation based on the prevalence in 861 a single-arm confirmatory diagnostic accuracy study Effects of bowel preparation on the 864 human gut microbiome and metabolome 866 Patterns of occult bleeding in asymptomatic colorectal cancer Diet and the gut microbiome: from hype to hypothesis Hoff 871 G. Long-term lifestyle changes after colorectal cancer screening: Randomised 872 controlled trial Changes in health behavior 1 year after testing negative at a colorectal cancer 875 screening: A randomized-controlled study Post-polypectomy colonoscopy 878 surveillance